TDLAF

 
Common Stock International Reporting
OTCQB
Verified Company Profile 2/27/2017
Contact Info
  • Level 18, 101 Collins Street
  • Melbourne, VIC 3000
  • Australia

Business Description


 
Financial Reporting/Disclosure
Reporting Status International Reporting: ASX - Australian Securities Exchange
Audited Financials Audited
Latest Report Jun 30, 2016 Annual Report
CIK 0000943502
Fiscal Year End 6/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: Australia
Year of Inc. 1989
Employees Not Available
Company Officers/Contacts
Justyn Stedwell Secretary
Company Directors
Jitto Arulampalam Chairman
Hongjen Chang
Service Providers
Accounting/Auditing Firm
BDO Audit
38 Station St
Adelaide, VIC, 5000
Australia
 
Securities Counsel
Fleur Lankesheer
2806 Ipswich Road,
Darra, Brisbane, QL, 4076
Australia
 
Investor Relations Firm

Not Available
Company History
  • Formerly=Progen Pharmaceuticals Ltd. until 11-2016
  • Formerly=Progen Industries Ltd. until 5-07
TDLAF Security Details
Share Structure
Market Value1 $7,396,069 a/o Mar 24, 2017
Authorized Shares 60,545,131 a/o Dec 16, 2014
Outstanding Shares 55,285,315 a/o Dec 16, 2014
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value No Par Value
Transfer Agent(s) Verified by Transfer Agent
Computershare Trust Company, N.A.
Shareholders
Shareholders of Record 5 a/o Dec 27, 2010
Non US Stock Exchange Listing
TDL - ASX - Australian Securities Exchange - Qualified
Short Selling Data
Short Interest 0 (-100%)
Jan 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security